#Oxford #UK #Brainomix #Health Technology #American Heart Association

Brainomix Partners with the American Heart Association

Chicago and Oxford, October 31, 2025 – Brainomix, a leading innovator specializing in AI-powered imaging tools for stroke and lung fibrosis, has announced its membership in the American Heart Association Center for Health Technology & Innovation's Innovators' Network. This collaboration aims to drive forward the development of sustainable and innovative health technologies.

Advancing Health Technology through Collaboration

The Innovators' Network is a consortium that facilitates connections among entrepreneurs, healthcare providers, researchers, and payers. The primary goal of this consortium is to spur innovation in cardiovascular and brain health technologies. By joining the Innovators' Network, Brainomix will have access to the Association's evidence-based scientific guidelines and clinical recommendations. This access is crucial as it will aid in the development of digital healthcare technologies that improve patient outcomes.

Opportunities for Members

Members of the Innovators' Network can engage in various collaborative efforts, including developing models for clinical outcome studies. This approach significantly reduces the high costs commonly associated with these studies when undertaken independently. Moreover, the initiative aids in linking scientific research to technology, offering evidence that such digital platforms can enhance healthcare outcomes—a priority for both healthcare providers and payers alike.

Dr. Robert A. Harrington, a past president of the American Heart Association and chair of the Health Tech Advisory Group, emphasized the importance of this initiative, stating, "The Center aims to advance the rapid, efficient, and effective development of healthcare technology. Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena."

Impacting Stroke Diagnosis and Treatment

Brainomix, known as the sole stroke-AI company within the Innovators' Network, is eager to collaborate with the American Heart Association to expand the role of AI in the assessment of strokes throughout the patient journey. Michalis Papadakis, CEO and Co-Founder of Brainomix, expressed enthusiasm about this partnership, saying, "We look forward to collaborating with the American Heart Association to enhance the role of AI in stroke assessment at all points of the patient pathway. This endeavor is crucial in enabling clinicians to make confident and impactful treatment and transfer decisions, ultimately leading to improved patient outcomes."

About Brainomix

Founded as a spinout from the University of Oxford, Brainomix has made significant strides in the field of AI medical imaging. The company is dedicated to facilitating precision medicine, thereby allowing for better treatment decisions specifically in stroke and pulmonary fibrosis. One of its flagship products, Brainomix 360 Stroke, represents the world’s first fully automated AI imaging platform designed specifically for acute stroke assessments. This innovative platform ensures that hospitals can make confident treatment and transfer decisions, independent of local resources or expertise.

In addition, the Brainomix 360 e-Lung technology utilizes AI-driven CT biomarkers to effectively identify, monitor, and predict disease progression in pulmonary fibrosis patients. With operations spanning over 20 countries, Brainomix maintains offices in the UK, Ireland, and the USA, remaining committed to pioneering technological advancements in healthcare.

For further information about Brainomix and its groundbreaking technologies, visit www.brainomix.com and follow their updates on social media platforms such as Twitter, LinkedIn, and Facebook.